Synthetic Biologics announced the formation of a clinical advisory board to support development of the company's constipation-predominant irritable bowel syndrome program.
The Company also announced that the lead investigator for the constipation-predominant irritable bowel syndrome program, Mark Pimentel, MD, has joined Synthetic Biologics as chairman of the clinical advisory board.
Dr. Pimentel is director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai Medical Center in Los Angeles.
Synthetic Biologics is a developer of anti-infective biologic and drug candidates targeting specific pathogens.
AGA Calls for More Transparency From CMS
The Growing Role of Biologics in Gastroenterology
The Company also announced that the lead investigator for the constipation-predominant irritable bowel syndrome program, Mark Pimentel, MD, has joined Synthetic Biologics as chairman of the clinical advisory board.
Dr. Pimentel is director of the Gastrointestinal Motility Program and Laboratory at Cedars-Sinai Medical Center in Los Angeles.
Synthetic Biologics is a developer of anti-infective biologic and drug candidates targeting specific pathogens.
More Articles on Gastroenterology:
9 Statistics on Gastroenterologist Compensation by LocationAGA Calls for More Transparency From CMS
The Growing Role of Biologics in Gastroenterology